Business
Update re: Broker
Update re: Broker.
About this update from Nuformix Plc
[{"type":"text","content":"\n \nRNS Number : 5692G Nuformix PLC 02 March 2018 \n\nNuformix plc\n(\"Nuformix\" or \"the Company\")\n \nUpdate re: Broker\n \nNuformix (LSE: NFX.L), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, notes the announcement today regarding the Company's broker Beaufort Securities Limited (\"BSL\") being placed into insolvency and that the Financial Conduct Authority (the \"FCA\") has imposed requirements on BSL to cease all regulatory activity. As a result BSL will no longer be able to provide broking services to the Company and the Board is therefore looking to make a new appointment of a broker to the Company in due course. \n \nNuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L. Follow Nuformix on Vox Markets: follow at: www.voxmarkets.co.uk/company/NFX\nand the Company's web site at: www.nuformix.com\n \nThis announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.\n \nENDS\n \nEnquiries:\n\n\n\n\nNuformix plc\nDan Gooding, Chief Executive Officer\n \n\n\n+44 (0)1223 423667\n \n\n\n\n\nGable Communications Ltd\nJohn Bick / Justine James\n\n\n+44 (0)20 7193 7463\n \n \n \n\n\n\n\nAbout Nuformix plc www.nuformix.com \n \nNuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules. \n \nNuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.\n \nNuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List und...